Diffuse alveolar hemorrhage and recombinant factor VIIa treatment in pediatric patients.
10.3345/kjp.2016.59.3.105
- Author:
Jeong A PARK
1
Author Information
1. Department of Pediatrics, Inje University Haeundae-Paik Hospital, Inje University College of Medicine, Busan, Korea. jeonga95@paik.ac.kr
- Publication Type:Review
- Keywords:
Child;
Diffuse alveolar hemorrhage;
Recombinant factor VIIa;
Vasculitis Thrombosis
- MeSH:
Adrenal Cortex Hormones;
Adult;
Child;
Diagnosis;
Extracorporeal Membrane Oxygenation;
Factor VIIa*;
Hematologic Neoplasms;
Hemorrhage*;
Humans;
Immunosuppressive Agents;
Off-Label Use;
Risk Assessment
- From:Korean Journal of Pediatrics
2016;59(3):105-113
- CountryRepublic of Korea
- Language:English
-
Abstract:
Diffuse alveolar hemorrhage (DAH) is a life-threatening pulmonary complication in patients with hematologic malignancies or autoimmune disorders. The current treatment options, which include corticosteroids, transfusions, extracorporeal membrane oxygenation (ECMO), and immunosuppressants, have been limited and largely unsuccessful. Recombinant activated factor VII (rFVIIa) has been successfully administered, either systemically or bronchoscopically, to adults for the treatment of DAH, but there are few data on its use in pediatric patients. The current literature in the PubMed database was reviewed to evaluate the efficacy and risk of rFVIIa treatment for DAH in pediatric patients. This review discusses the diagnosis and treatment of DAH, as well as a new treatment paradigm that includes rFVIIa. Additionally, the risks and benefits of off-label use of rFVIIa in pediatric patients are discussed.
